Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T. Shirono T, et al. Among authors: murotani k. Hepatol Commun. 2022 Sep;6(9):2594-2604. doi: 10.1002/hep4.2016. Epub 2022 Jun 3. Hepatol Commun. 2022. PMID: 35656864 Free PMC article.
Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.
Tanaka T, Suzuki H, Miwa K, Ushijima T, Nagasu S, Fukahori M, Ishii K, Nakamura T, Iwamoto H, Masuda A, Sakaue T, Koga H, Akagi Y, Murotani K, Torimura T. Tanaka T, et al. Among authors: murotani k. Oncol Lett. 2022 Jul 19;24(3):318. doi: 10.3892/ol.2022.13437. eCollection 2022 Sep. Oncol Lett. 2022. PMID: 35949619 Free PMC article.
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y. Niizeki T, et al. Among authors: murotani k. Target Oncol. 2022 Nov;17(6):643-653. doi: 10.1007/s11523-022-00921-x. Epub 2022 Oct 22. Target Oncol. 2022. PMID: 36272060 Free PMC article.
Tumor size  ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Tsutsuyama M, et al. Among authors: murotani k. World J Surg. 2020 Jan;44(1):194-201. doi: 10.1007/s00268-019-05198-2. World J Surg. 2020. PMID: 31552460
Clinical impact of additional therapy for residual pancreatic cancer.
Yamada S, Sonohara F, Tashiro M, Murotani K, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujii T, Kodera Y. Yamada S, et al. Among authors: murotani k. Surg Today. 2020 May;50(5):440-448. doi: 10.1007/s00595-019-01900-y. Epub 2019 Oct 24. Surg Today. 2020. PMID: 31650262
337 results